60 DEGREES PHARMACEUTICALS, INC.(SXTP)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $1.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
SXTP Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for 60 DEGREES PHARMACEUTICALS, INC. (SXTP), a Healthcare sector company. SXTP is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $1.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), 60 DEGREES PHARMACEUTICALS, INC. reports quarterly revenue of $207.9K, net income of $-2.3M, free cash flow of $-2.2M. Top institutional holders of SXTP by reported 13-F value include Kathmere Capital Management, CITADEL ADVISORS, XTX Topco Ltd, based on the most recent SEC filings. SXTP trades on the Nasdaq exchange and files with the SEC under CIK 1946563. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SXTP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for 60 DEGREES PHARMACEUTICALS, INC. directly from SEC EDGAR.
Revenue
Q2 2026
$207.9K
Net Income
Q2 2026
$-2.3M
Free Cash Flow
Q2 2026
$-2.2M
D/E Ratio
Q2 2026
0.06
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+65.5% YoYNet Income
+7.3% YoYOperating Income
+20.1% YoYEPS (Diluted)
+84.2% YoYTotal Assets
-6.8% YoYTotal Debt
+0.0% YoYOp. Cash Flow
-21.3% YoYFree Cash Flow
-21.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $1.0M +65.5% | $607.6K +139.6% | $253.6K +13.6% | $223.2K | — |
| Net Income | $-7.4M +7.3% | $-7.9M -111.0% | $-3.8M +39.1% | $-6.2M | — |
| Operating Income | $-7.8M +20.1% | $-9.7M -88.5% | $-5.2M -194.5% | $-1.8M | — |
| EPS (Diluted) | $-11.73 +84.2% | $-74.17 -558.0% | $-11.27 -2167.6% | $-0.50 | — |
| Total Assets | $5.4M -6.8% | $5.8M -26.0% | $7.8M +500.0% | $1.3M | — |
| Total Debt | $158.8K +0.0% | $158.8K +0.0% | $158.8K -99.1% | $16.9M | — |
| Operating Cash Flow | $-6.8M -21.3% | $-5.6M -24.3% | $-4.5M -349.8% | $-1.0M | — |
| Free Cash Flow | $-7.0M -21.5% | $-5.8M -25.0% | $-4.6M | — | — |
Get alerted when SXTP's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for 60 DEGREES PHARMACEUTICALS, INC. including:
Top Institutional Holders of SXTP
Kathmere Capital Management, LLC
$466.6K265,100 shCITADEL ADVISORS LLC
$39.4K22,362 shXTX Topco Ltd
$31.0K17,639 shKovack Advisors, Inc.
$26.4K15,000 shGEODE CAPITAL MANAGEMENT, LLC
$25.6K14,551 shUBS Group AG
$23.9K13,592 shBARCLAYS PLC
$1.9K1,052 shOSAIC HOLDINGS, INC.
$44.0025 sh
| Fund | Value | Shares |
|---|---|---|
| Kathmere Capital Management, LLC | $466.6K | 265,100 |
| CITADEL ADVISORS LLC | $39.4K | 22,362 |
| XTX Topco Ltd | $31.0K | 17,639 |
| Kovack Advisors, Inc. | $26.4K | 15,000 |
| GEODE CAPITAL MANAGEMENT, LLC | $25.6K | 14,551 |
| UBS Group AG | $23.9K | 13,592 |
| BARCLAYS PLC | $1.9K | 1,052 |
| OSAIC HOLDINGS, INC. | $44.00 | 25 |
More Healthcare Companies
View all Healthcare →Put SXTP on your watchlist
Track score changes the day 60 DEGREES PHARMACEUTICALS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is SXTP a good stock to buy?
13F Pro's AI-powered analysis of 60 DEGREES PHARMACEUTICALS, INC. (SXTP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SXTP are available on the SXTP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. SXTP is classified as a small company.
Which hedge funds own SXTP?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SXTP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of 60 DEGREES PHARMACEUTICALS, INC.'s investment landscape.